Daily Brief Health Care: Vivani Medical, Medcaptain Medical Technology, Dr Lal PathLabs Ltd, Immix Biopharma Inc, MDxHealth SA, Oncology Institute and more

• Vivani Medical has set Oct 8, 2025 as teh record date for its earlier announced spin-off of its neuromodulation subsidiary, Cortigent Inc.
• Vivani will retain its focus on its GLP-1 implant pipeline for metabolic disease. Investors get clean exposure to two very different growth narratives: neuromodulation (BCI) and drug implants.
• If executed properly, this spin-off could unlock meaningful valuation uplift particularly for Cortigent in a promising but under-served medtech space.

• Medcaptain Medical Technology (MMT) is looking to raise about US$100m in its upcoming Hong Kong IPO. The deal will be run by Morgan Stanley and Huatai International.
• Medcaptain Medical Technology is a global medical solution provider specializing in life support, minimally invasive intervention, and in vitro diagnostics. 
• Its products are widely used across hospitals, clinics, testing facilities, and home care scenarios, addressing the needs of critical care, surgery, and diagnostics.

• Dr Lal PathLabs Ltd (DLPL IN) started FY26 on a strong note, achieving double-digit improvement in all key parameters, mainly driven by volume resulting from expanding geographic presence.
• Steady secular rise in the number of tests as well as sample per patient is helping DLPL to deliver healthy top and bottom line growth, without indulging in price hike.
• For FY26, the company guided for 11–12% revenue growth (acceleration from 10.5% revenue growth in FY25) and expects FY26 EBITDA margin will be better than initial expectation of 27%.

Immix Biopharma has announced that its US-based NEXICART-2 trial, evaluating lead CAR-T asset NXC-201 in amyloid light chain amyloidosis (ALA), has surpassed the 50% enrolment milestone. The news provides affirmation that this key study is progressing to plan, in line with prior guided timelines. Enrolment will continue to be a strategic priority as management works toward a biologics licence application (BLA) submission, which we estimate will take place after the trial concludes in mid-2026. Should the clinical data continue to be supportive, NXC-201 could become the first CAR-T therapy for ALA, a debilitating condition that currently lacks durable treatment options.

Key points (machine generated)

• MDX Health projects $108-110 million in revenue for 2025, driven by its ConfirmMDx and GPS tests.
• The company anticipates achieving AEBITDA breakeven by 2Q25, following 16 consecutive quarters of over 20% growth.
• Despite strong performance, MDXH’s stock is undervalued at 1.3x sales, with CEO Michael McGarrity implementing strategies for improvement.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)

• The Oncology Institute, Inc. (TOI) is a prominent cancer care organization in the U.S. that served over 72,000 patients in 2024.
• TOI operates in 16 markets across 5 states, primarily California and Florida, managing care for about 1.9 million individuals through various treatment models.
• Revenue is generated from three segments: Patient Services (52%), Dispensary (46%), and Clinical Trials (2%), with a focus on patient health and cost management.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.